![]() |
JOURNAL TOOLS |
Publishing options |
eTOC |
To subscribe |
Submit an article |
Recommend to your librarian |
ARTICLE TOOLS |
Reprints |
Permissions |
Share |


YOUR ACCOUNT
YOUR ORDERS
SHOPPING BASKET
Items: 0
Total amount: € 0,00
HOW TO ORDER
YOUR SUBSCRIPTIONS
YOUR ARTICLES
YOUR EBOOKS
COUPON
ACCESSIBILITY
REVIEWS
Minerva Medica 2007 October;98(5):603-23
Copyright © 2007 EDIZIONI MINERVA MEDICA
language: English, Italian
Targeted therapies in solid tumours: results and promises
Pantaleo M. A., Saponara M., Nannini M., Biasco G.
“L. and A. Seragnoli” Institute of Medical Hematology and Oncology S. Orsola-Malpighi Polyclinic, Bologna, Italy
In these last few years novel approaches to the treatment of solid tumours have been proposed. Therapeutic agents addressed to specific functions of the neoplastic cells seems to be very promising tools, with a low grade of toxicities. These agents are the basis of the so called targeted therapies. Small molecules inhibiting the proliferative cascade of the cancer cells and monoclonal specific antibodies against growth factor or vascular endothelial growth factor have been claimed as the promise in cancer therapy. Unfortunately, the very good results obtained in preclinical experiments have not been completely confirmed in the clinical practice. A selection of patients who could have beneficial effects from the novel agents is mandatory to avoid inappropriate therapies and also unjustified expenses.